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Abstract

BACKGROUND: Aducanumab (ADUHELM ) was approved
for the treatment of Alzheimer's disease (AD) in the US. This
approval was supported by an effect on the cerebral amyloid
plaque load and evidence of cognitive efficacy to be confirmed
in post-marketing trials. Other anti-amyloid antibodies are
under investigation in phase III (donanemab, lecanemab,
gantenerumab) and have shown preliminary evidence of a
cognitive benefit in phase II trials. Although these agents target
a small segment of patients with mild cognitive impairment
due to AD or mild AD dementia, their advent will change the
design of future clinical trials both for anti-amyloid and nonamyloid drugs. These changes will promote the selection of
patients in clinical trials by amyloid and tau biomarkers that
identify patients with appropriate biology and may follow
the treatment response to approved amyloid antibodies. The
use of these agents creates the opportunity to test combined
drug therapies and to conduct comparative assessments with
innovative therapies and newly approved drugs available
in clinical practice. Blood-based AD biomarkers should be
implemented in research and could facilitate the recruitment
into clinical trials. Anti-amyloid antibodies will have positive
(e.g., more early diagnosis) and negative impacts (some subjects
will be reluctant to participate in trials and risk assignment
to placebo) on AD trials in the immediate future. We present
the results of the CTAD Task Force on this topic, in Boston,
November 6, 2021.
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Accepted for publication April 19, 2022
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Introduction

R

ecently, aducanumab (ADUHELM TM ) was
approved for the treatment of Alzheimer's
disease (AD) in the United States (US). This antiamyloid monoclonal antibody demonstrated an effect
on the cerebral amyloid plaque burden and showed
preliminary evidence of efficacy (in the PRIME phase
Ib trial and the EMERGE but not ENGAGE phase III
trials) in patients who had received the high doses
(1–4). Numerous other phase III trials with anti-amyloid
antibodies are underway and will potentially add to the
repertoire of anti-amyloid therapies for the treatment
of AD. Gantenerumab is currently being studied
in the GRADUATE program (NCT03444870) and the
GRADUATION trial (NTC04592341), donanemab in the
TRAILBLAZER-ALZ 2, 3, 4 and EXT trials (NCT04640077,
NCT04437511, NCT05026866 and NCT05108922) and
lecanemab in the CLARITY (NCT03887455) and AHEAD
3-45 (NCT04468659) trials. These therapies could
markedly change the therapeutic landscape of AD.
393

THE FUTURE OF AD CLINICAL TRIALS WITH THE ADVENT OF ANTI-AMYLOID THERAPIES

Anti-amyloid antibodies may have both positive and
negative impacts on AD trials in the immediate future
(5). This includes potential diversion of resources from
clinical research to support clinical care including staff
time and space. It may impact enrollment and recruitment
if patients need to choose between an approved
treatment or a clinical trial/observational study. The
approval of ADUHELM TM and the potential arrival of
other anti-amyloid antibodies for clinical practice may
change the design of future therapeutic trials both for
anti-amyloid and non-amyloid therapies. To date, the
approval of ADUHELM TM beyond the US is uncertain
(refusal recommended by Europe Medicines Agency but
ongoing re-examination, request for more data by the
Japanese Health Ministry) and some of the considerations
discussed in this paper may not be applicable globally
(6). Furthermore, using clinical trials criteria, estimates of
eligible subjects for aducanumab are low and range from
8-20% of patients with AD (7).
The EU/US CTAD Task Force met in November
2021 at Boston to discuss this topic, bringing together
a global group of clinical investigators from academia
and industry. The CTAD Task Force assessed the
consequences of advent of anti-amyloid therapies for
amyloid and non-amyloid trial design:
1) What issues need to be addressed in future trials of
ADUHELMTM?
2) What are the consequences of ADUHELMTM approval
for inclusion criteria in future clinical trials?
3) What is the place for biomarkers in labeling of new
agents and for blood-based biomarkers in future AD
clinical trials?
4) What are consequences in prevention trials such as
AHEAD 3-45 and DIAN-TU NextGen?

Aducanumab: prescribing instructions,
appropriate use recommendations and issues
to be resolved
Label prescribing instructions
ADUHELMTM is a human anti-amyloid monoclonal
antibody indicated for the treatment of AD (3). According
the Food and Drug Administration (FDA) updated label,
ADUHELMTM can be prescribed for patients with mild
cognitive impairment (MCI) or mild dementia due to
AD (4). The cognitive benefit will require verification
in confirmatory post-marketing trials to maintain this
indication. This indication was approved using an
accelerated approval regulatory pathway supported by
removal of amyloid plaques observed in phase Ib and
III trials. EMERGE and ENGAGE trials showed that
higher exposures to ADUHELMTM were associated with
greater effect on cognitive decline and cerebral amyloid
plaque load. The reduction of amyloid plaques was
demonstrated on amyloid positron emission tomography
(PET). An association between reduction in cerebral

amyloid burden and cognitive decline (Clinical Dementia
Rating-sum of boxes [CDR-SB] as primary outcome)
was observed. In sub-studies, ADUHELMTM with high
doses showed an impact on tau pathology both by
decreasing cerebrospinal fluid (CSF) levels of p-tau and
t-tau (in the EMERGE study [n=17] but not significantly
in the ENGAGE study [n=18]), and brain tau pathology
assessed by tau PET in the medial temporal, temporal,
and frontal but not in parietal and cingulate regions
(pooled analysis, n=37). As mentioned previously, the
effects of ADUHELMTM on AD biomarkers is described
in the label but the need for a positive amyloid biomarker
to qualify for therapy is not explicitly required in the
updated label.
For the monitoring of amyloid related imaging
abnormalities (ARIAs), the US FDA Prescribing
Instructions recommend obtaining recent (within one
year) brain magnetic resonance imaging (MRI) before
initiating therapy and MRIs before the 7th infusion
(first high dose) and 12th infusion (sixth high dose).
The treatment may be continued with caution if new
microhemorrhages of focal superficial siderosis are
observed. The label prescribing instructions are different
from the criteria for inclusion in EMERGE and ENGAGE
trials creating uncertainty and potentially posing a
problem regarding the safety of ADUHELMTM in clinical
practice.

Appropriate use recommendations and issues in
clinical practice
Currently, many subjects with a family history of
AD consult physicians at an early stage of symptoms.
If the drug is available, both patients and physicians
may change their behavior and practice and this trend
will probably increase (8). An expert panel developed
appropriate use recommendations to help clinicians
translate the Prescribing Instructions and clinical trial
data into patient care (9).
Several studies have shown that the inclusion and
exclusion criteria from EMERGE and ENGAGE studies
are probably too restrictive and selected patients not
representative of “real world” populations. For patients
enrolled in Medicare, 91.0% with AD and 85.5% with MCI
met at least 1 trial exclusion criterion. The most common
exclusion criteria identified were chronic kidney and
cardiovascular diseases, anticoagulation, and advanced
age (over 85 years) (7). In a geriatric environment of
a European university hospital (Italy), the results of
another study are similar (10). As judged by the clinicians,
patients were ineligible for ADUHELM TM due to age,
low education level, absence of a caregiver, cognitive
impairment too severe, compromised autonomy, a
major laboratory abnormality or/and a significant brain
vascular disease. Thus, only a very low proportion of
patients (<1%, potentially underestimated) with
cognitive disorders would be potentially eligible from
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Table 1. Examples of amyloid antibodies effect on binary amyloid status assessed by PET
Drugs

Trials

Participants

Negative amyloid status (%)
1 year-treatment

2-year treatment

3-year treatment

Gantenerumab (14,15)

Open-label extensions of SR and MR (high doses) *

Prodromal to moderate AD

37

51

81

Donanemab (13)

TRAILBLAZER ALZ

Prodromal to mild AD

59.8

UK

UK

Lecanemab (16)

Phase IIb trial (10-mg/ kg biweekly dose)

Prodromal to mild AD

57

UK

UK

SR, SCarlet RoAD; MR, Marguerite RoAD; AD, Alzheimer Disease; UK, UnKnown; *15% of participants had a negative amyloid status at baseline visit of open-label
extensions.

ADUHELMTM in clinical practice. The expert panel made
multiple recommendations that expand the population
beyond the trial population.
In contrast to the clinical trials criteria, the label
Prescribing Instructions are broad. The expert panel
recommendations suggest that the appropriate use
of ADUHELM TM in practice should replicate the use
of aducanumab in the phase III trials in particular
the confirmation of a positive amyloid status prior to
prescription (9). The indications would be more limited
and safety recommendations more restrictive than the
information provided in the label Prescribing Instructions
(9). MRI monitoring may be needed more often and
earlier than suggested by FDA, particularly in APOE4
carriers.

Safety issues to be addressed in post-marketing
trials
Many issues need to be addressed in future trials
with anti-amyloid therapies: ARIA monitoring and
management, special circumstances (autosomal
dominant AD, atypical forms, Down syndrome with
cognitive decline, and others), and indications and
contraindications in the “real-world”. One major concern
to address is the growing number of older persons taking
anti-coagulant medications who have been excluded from
clinical trials and considered also as contraindication by
expert panel recommendations. Impaired clotting may
increase the risk of making ARIA-H (ARIA-Hemorrhage)
side-effects more significant. Post-marketing trials with
aducanumab should clarify these points to optimize use
of anti-amyloid antibodies in practice. Three trials are
planned by the sponsor to complete phase III data: 1) a
re-dosing phase III study (EMBARK, NCT04241068), 2)
a phase IV confirmatory study, and 3) an observational
Phase IV 5-year study called ICARE-AD (NCT05097131),
introduced at the Alzheimer's Association International
Conference 2021 (Amsterdam), to assess real-world
effectiveness and safety. The advent of aducanumab will
also allow comparison studies such as the TRAILBLAZER
ALZ IV study (NCT05108922) which will compare the
effects of donanemab and aducanumab on brain amyloid
plaque load.

What are the potential consequences for
inclusion criteria and sample size in future
clinical trials?
Removal of amyloid will have consequences for future
trial design including participation criteria. The AD drug
development pipeline has many classes of drugs affecting
different targets (11). However, even non-amyloid target
trials include subjects based on amyloid biomarkers
(CSF or PET and perhaps blood-based markers in the
future). High doses of amyloid antibodies can change
the amyloid status of participants and this effect seems
to be cumulative over time (see table 1). In this context,
how will recruitment into new AD clinical trials work
if patients are taking anti-amyloid treatments and are
potentially missing this characteristic AD marker?
Patients whose amyloid plaque burden has been
reduced to undetectable levels no longer meet amyloidtau-neurodegeneration (AT[N]) criteria for AD (12). A
solution to consider could be the use of tau biomarkers as
inclusion criteria in future trials. Currently, the selection
of subjects based on tau biomarkers in clinical trials
is difficult. In the phase II TRAILBLAZER-ALZ trial,
selection by biomarker clearly affected screening and
enrollment (screen failure of 30% due to tau-PET status)
(13). Anticipating that anti-amyloid antibodies can
influence tau pathology level and soluble tau biomarkers;
patient selection is likely to be even more difficult in the
future.
By acting on amyloid pathology, antibodies also
affect a multitude of other processes involved in AD
including tau pathology and soluble tau biomarkers.
This was demonstrated in clinical trials (see table 2)
and is evident in data from the Alzheimer Disease
Neuroimaging Initiative (ADNI) (17). This extensive
evidence evokes a close relationship between amyloid
and tau; tau pathology spread accelerates once amyloid
load reaches a critical cut-off launching a cascade of
metabolic, degenerative, and cognitive changes. Tau-PET
studies highlighted a temporal and spatial pattern of tau
pathology dependent on prior Aβ deposition and related
to subsequent cognitive decline.
It is important to consider that decreasing amyloid
pathology will change this cascade of events and this
should be considered in the recruitment of future clinical
trials including sample size and power calculation.
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Table 2. Effect of amyloid antibodies on tau biomarkers assessed by PET and CSF measures
Drugs

Trials

Population

Doses

Effect on Tau-PET

Effect on p-tau in CSF

Gantenerumab (19, 20)

SCarlet RoAD

Prodromal AD

105 or 225 mg

UK

Significant decrease of
p-tau181 at 2 years

DIAN-TU

Asymptomatic and
symptomatic DIAD

Doses increased during
the study

UK

Significant decrease of
p-tau181 at 2 and 4 years

Donanemab (13, 21)

TRAILBLAZER ALZ

Prodromal to mild AD

1400 mg

No significant effect on
global tau load at 76
weeks but significant
change in neurofibrillary
tangles in the parietal
and frontal lobes

Significant decrease of
p-tau217 at 76 weeks

Lecanemab (16)

Phase II

Prodromal to mild AD

10 mg/kg bi-weekly and
monthly

UK

Significant decrease of
p-tau181 at 18 months

Aducanumab (2)

EMERGE and ENGAGE

Prodromal to mild AD

Low and high doses

Significant decrease of
tau medial temporal load

Significant decrease on CSF
and blood p-tau181

DIAN-TU, Dominantly Inherited Alzheimer Network Trial Unit; DIAD, Dominantly Inherited Alzheimer's Disease; AD, Alzheimer Disease; UK, UnKnown.

Amyloid and tau effects will slow disease progression
and achieving a 0.5 drug-placebo difference on the CDRSB will likely require a larger sample size in future clinical
trials. Power calculation estimates might increase sample
size by 30-50% to detect drug-placebo differences in a
population that progresses more slowly than untreated
AD. Alternatively, removing amyloid plaques may have
an additive or synergistic effect on tau drug efficacy,
by removing the amyloid mechanisms that drive tau
spread pathophysiology including tau over-production
due to amyloid plaques (18). Anti-tau drugs may be more
effective in a population that has received anti-amyloid
treatment, but this may require a much longer trial to
demonstrate.

Place of blood-based and non-blood-based
biomarkers in AD trials
How to include biomarkers in the product label?
As mentioned above, ADUHELM TM is indicated in
patients with MCI or mild dementia stage of AD (4). This
indication is not based on biomarkers on the Prescribing
Instructions whereas its approval is supported mainly
by removal of amyloid plaque load. Biomarkers are
mentioned only in the label section 14 for detailing the
impact of ADUHELMTM on amyloid and tau pathologies.
In 2021, more than 40% of phase II and III trials used
biomarkers including amyloid PET or CSF as inclusion
criteria (22). This point raises the question of how AD
biomarkers should be mentioned in the label in the
field of AD, especially for the indication(s). We have
many examples of drugs whose indication is based on
biomarkers in the cardiovascular field:
- The first indication of LIPITOR (atorvatin) approved
in 1999 is clinical and second indication is based on
biomarker (reduce elevated total-C, LDL-C, apo B, and
TG levels and increase HDL-C in patients with primary
hyperlipidemia).

- CRESTOR (rosuvastatin) has been approved in 2003, all
indications are based on biomarkers.
- TRUCILITY (dulaglutide) is indicated as “an adjunct to
diet and exercise to improve glycemic control in adults
with type 2 diabetes mellitus”. The second indication is
clinical.
With accelerated approvals, a biomarker should
be “reasonably likely” to predict clinical benefit. The
reduction of amyloid plaque load is associated with
the slowing of cognitive decline in several studies (2,
13, 16, 23). However, the clinical benefit of antiamyloid antibodies may be mediated by secondary
mechanisms beyond removal of amyloid pathology
including impact on tau toxicity, neuro-inflammation,
or neurodegeneration. These secondary affects need to
be accommodated in product labeling (if relevant data
of sufficient quality are generated) as well as in future
trial design including non-amyloid trials. More studies
are needed to confirm and use amyloid plaque load
as a surrogate marker similar to the use of glycemic
or cholesterol levels in the cardiovascular field. Other
potential surrogate biomarkers include tau PET, soluble
amyloid-beta42/40, and soluble forms of tau. If
confirmed as a predictive surrogate outcome, amyloid
plaque burden or another biomarker, could be utilized as
a primary endpoint could allow for shorter future trials
with fewer participants and thus accelerate the discovery
of new therapies. As information evolves, biomarkers
(plasma or otherwise) that define inclusion criteria and
that may reflect efficacy could be included in labels.

Place of blood-based biomarkers for future AD
trials?
To date, amyloid level assessed by PET or CSF
measures are the most widely used biomarkers to select
participants for clinical trials of AD disease-modifying
therapies. However, screening by amyloid PET is
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difficult to generalize in clinical practice given its cost
and limited access (in Europe and much of the rest of
the world). Thus, the use of innovative therapies may be
difficult in clinical practice, especially if biomarkers are
included in the label of new treatments in the future. In
the Multidomain Alzheimer Prevention Trial (MAPT),
low plasma Aβ42/40 was associated with an increased
cognitive decline in non-demented participants (MCI and
cognitively unimpaired subjects) over time (24). In the
Biomarkers For Identifying Neurodegenerative Disorders
Early and Reliably (BioFINDER) study, blood-based
biomarkers (Aβ42/40 ratio, p-tau217 and neurofilament
light chain, NfL) predict cognitive decline and incident
AD dementia in cognitively unimpaired subjects (25). In
the BioFINDER and ADNI studies, a model combining
blood p-tau, memory with executive tests, and
apolipoprotein E (APOE) genotype predicts the risk of
developing dementia in subjects with subjective cognitive
decline and MCI (area under the curve = 0.90-0.91) (26).
Using CSF biomarkers instead of blood-based biomarkers
did not improve the prediction accuracy of this model.
The presence of amyloid plaques was detected with
similar factors across ADNI, BioFINDER, and Australian,
Imaging, Biomarkers and Lifestyle (AIBL) cohorts (27).
These findings suggest that blood-based biomarkers
(Aβ42/40 ratio or/and p-tau) may be used to identify in
non-demented subjects the risk of cognitive decline and
for developing AD dementia. The use of blood-based
biomarkers could certainly facilitate recruitment with
more cost and time effective screening or prescreening
by reducing the number of patients that need to go on to
more advanced diagnostics prior to trial qualification or
exclusion. Exploratory economic analyses from the ADNI
study showed that the use of blood amyloid biomarkers
as a prescreening tool prior to amyloid PET significantly
reduced screening cost expected in an AD prevention trial
(28). The deployment of blood-based biomarkers could
also simplify similarly the use of innovative therapies in
clinical practice in the future.

The example of DIAN-TU program
DIAN-TU NextGen: background and objectives
The Dominantly Inherited Alzheimer Network Trials
Unit (DIAN-TU) study observed no cognitive impact
of lower dose gantenerumab and solanezumab in
symptomatic and asymptomatic Dominantly inherited
Alzheimer's disease (DIAD). However, gantenerumab
demonstrated an effect on AD biomarkers, decreasing
cerebral amyloid load (Pittsburgh Compound-B [PIB]PET), and measures of t-tau, p-tau181, and NfL in CSF
(19). In view of its encouraging effects on biomarkers,
an exploratory open-label extension with gantenerumab,
testing of another anti-amyloid monoclonal antibody
(lecanemab), and non-amyloid treatments are planned
in the DIAN-TU NextGen program. Tau pathology is

an attractive target among non-amyloid targets and
tau may be playing a role in the early stages of DIAD.
The early soluble tauopathy hyperphosphorylation
(increase in p-tau217 and p-tau181) with the onset of
fibrillar amyloid pathology seems to play a determining
role in the asymptomatic stages of AD, whereas tau
aggregation (assessed by tau-PET) is more involved in
the symptomatic stages (29). The strongest association
between cognitive performance and AD pathology is
with neurofibrillary tangles, and markers of brain tau
pathology may be good biomarkers to track and stage
cognitive decline (better than soluble forms of p-tau181
or 217). These data are crucially important and, if these
hypotheses confirmed, should be taken into consideration
in the design of future clinical trials evaluating antitau therapies as informed by DIAN-TU NextGen
observations.
The advent of anti-amyloid therapies has also provided
opportunities to launch combination trials, to provide
potentially greater biologic and clinical benefit, to
improve biological understanding of the relationship
between amyloid and tau pathologies, and to better
understand the drug impact of anti-amyloid antibodies
on multiple tau and other downstream mechanisms.
In this context, the specific aims of the DIAN-TU Tau
NexGen are: 1) to demonstrate biological engagement
of tau and/or combined drugs to significantly decrease
tau aggregation measured by tau-PET, 2) to determine if
neurodegeneration, hypometabolism, and inflammatory
AD processes show fewer changes in the active treatment
group compared to the control group and 3) to show
potential slowing of cognitive decline to support the
transition to phase III validation studies.

How to account for the advent of anti-amyloid
therapies in DIAN-TU Tau NextGen design?
To take advantage of the advent of anti-amyloid
antibody therapies, changes in the design of the trials
are needed. The ability to test anti-tau monotherapy
in future drug arms is likely limited, especially for
symptomatic participants who may desire treatment with
available anti-amyloid treatment. Allowing anti-amyloid
therapies could be required for participant recruitment
and retention. The segregation of participants across
symptomatology (asymptomatic vs symptomatic) and/
or tau pathology levels (negative vs positive status), the
order of administration (treat tau first or amyloid first
or at the same time?) and the duration of monotherapy
should be considered in future designs. Given these
design considerations, the DIAN-TU tau next generation
platform has designed trials of anti-tau therapies in the
following way (see Figure 1). In symptomatic patients,
anti-amyloid drug would be administered first for 6
months, then adding an anti-tau drug (randomization
1:1). In asymptomatic subjects, an anti-tau drug would
be administered first for 12 months (randomization
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Figure 1. Anti-tau therapies in the DIAN-TU tau next generation platform

CDR, Clinical Dementia Rating.

1:1), followed by the addition of an anti-amyloid drug.
The use of biomarkers as surrogate endpoints and as
inclusion criteria must be adapted to stage of the disease.
In asymptomatic participants, CSF p-tau, t-tau and NfL
could be used as endpoints and negative tau-PET or CDR
0 as inclusion criteria. In symptomatic patients, tau-PET
and neurodegeneration biomarkers (FDG-PET, NfL, and
brain atrophy) could be used as endpoints and positive
tau-PET or CDR>0 as inclusion criteria. The first trial arm
utilizing this design has launched with lecanemab and
E2814, an anti-tau antibody (NCT #).

Non-DIAN-TU Trial Design Considerations
The approval of ADUHELMTM must be accommodated
in future trials of patients who meet appropriate use
criteria. Several options are available. First, patients on
ADUHELM TM might be excluded from trials of novel
therapies as is currently done in some trials where
the standard of care with donepezil or memantine is
excluded. This must be considered from an ethical
perspective since delay of symptomatic therapies may
have different consequences from delay of a diseasemodifying therapies (DMT). Second, patients may be
allowed into trials irrespective of their treatment with
other stable DMTs such as aducanumab with planned
analyses based on the presence or absence of the DMT
or recruitment may be stratified based on DMT status.
This approach will have effects on expected effects size,
power calculations, and sample sizes. Third, comparative
studies could be conducted to determine the relative of
clinical efficacy, biomarker efficacy, or safety of the agents
in the trial. These could have superiority, non-inferiority,

of mixed (e.g., non-inferior clinical efficacy and superior
safety) designs. These approaches can be considered as
the field matures and experience with DMTs increases.

Conclusion
The advent of anti-amyloid therapies in clinical
practice will have both positive and negative effects
on future clinical trials. These changes will not have
impact world-wide at first, at present ADUHELMTM has
received approval only in the US. Furthermore, antiamyloid immunotherapies will target a small segment
of the AD population. The arrival of new treatments will
likely change the behavior of general practitioners (GPs),
patients and their families. The lack of effective treatment
is one of the main reasons for patients not to go for
consultation and for GPs not to refer to a memory clinic.
The availability of a treatment should encourage early
diagnosis of AD. The negative effects of the approval of
aducanumab are related to the potentially more difficult
recruitment, the interest in future trials could be reduced
in favor of an approved treatment. Removal of brain
amyloid pathology by anti-amyloid antibodies will also
have consequences in future trial design for selection of
participants.
The advent of new treatments is also an opportunity
to test the efficacy of combined therapies and to provide
comparison trials with approved or emerging drugs. In
particular, combining anti-tau therapies with the antiamyloid effect of approved therapies is a compelling
challenge and opportunity for future clinical trials. In
future therapeutic trials, biomarkers can be used to better
predict cognitive decline and treatment efficacy. Tau-
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PET appears to be a promising biomarker to predict
the cognitive change in symptomatic stages of AD.
Blood biomarkers could be implemented for selection
and monitoring drug response in asymptomatic stages.
Once validated as surrogate endpoints, these biomarkers
should be described in the label indications and not only
to report the non-clinical effects.
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